Based on preclinical studies that proved synergy between CDK4/6 inhibitors and PI3K inhibitors, a phase I open label dose-escalation study tested GDC-0077 as a single agent or in combination with letrozole/fulvestrant and Palbociclib for the treatment of locally advanced or metastatic PIK3CA-mutant BC. This evidence concerns the gene PIK3CA and breast cancer.